Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Net Margin · Q1 FY2026 · quarter ended Mar 2026

Net margin widens to -31.5%

Net margin was -31.5% in Q1 FY2026, up 30.8 pp from a year earlier. On a trailing-twelve-month basis it was -1.8%, up 57.3 pp year over year. Over 3 fiscal years it widened by 304.0 pp.

Context

  • Net margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether net margin reaches the consensus estimate from 1 analysts of -2.1% for the fiscal year ending Dec 2026, up from -5.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-31.5%-68.2 pp QoQ
Last fiscal yearDec 2025
-5.6%+9.9 pp YoY
LTMMar 2026
-1.8%+57.3 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+30.8 pp+15.1 pp-15.7 pp
1 year+9.9 pp+3.5 pp-6.4 pp
3 years+304.0 pp+22.6 pp-281.4 pp
5 years+36.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-5.6%
Year-over-year change
+9.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How ESPR compares with its peers on the latest reported figures

  • ESPR's LTM Mar 2026 net margin of -1.8% is the 4th highest of the 8 companies compared; the peer median is -7.3%.
  • Its year-over-year change of +57.3 pp is the highest of 8, against a peer median of -18.7 pp.
  • Over three fiscal years its change of +304.0 pp compares with a peer median of -6.0 pp.
ESPR Competitors Peer median
Net Margin for ESPR and competitors
Company Period LTM level YoY 3-year change
SIGASIGA Technologies, Inc.LTM Mar 202621.6% -18.7 pp-6.0 pp
SNDLSNDL Inc.LTM Mar 2026-1.2% +10.4 pp+45.4 pp
EBSEmergent BioSolutions Inc.LTM Mar 2026-1.3% +12.4 pp+26.0 pp
ESPREsperion Therapeutics, Inc.LTM Mar 2026-1.8% +57.3 pp+304.0 pp
OFIXOrthofix Medical Inc.LTM Mar 2026-7.3% +10.5 pp-6.9 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-137.1% -37.1 pp-74.0 pp
RGNXREGENXBIO Inc.LTM Mar 2026-330.2% -229.6 pp+134.9 pp
ABSIAbsci CorporationLTM Mar 2026-6450.8% -4218.6 pp-2288.3 pp
CRVSCorvus Pharmaceuticals, Inc.FY2025— ——
OLMAOlema Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding ESPR) -7.3%-18.7 pp-6.0 pp

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.